stockrowNektar Therapeutics
NKTR Healthcare Biotechnology
Nektar Therapeutics' revenue for fiscal 2025 (year ended December 2025) was $55.2 million, down 43.9% from fiscal 2024.
- Revenue
- −9.34%
- EPS
- +58.3%
- Free cash flow
- −65.7%
Quarter to June 2026, against a year earlier
Follow NKTR
Alert me
Nektar Therapeutics (NKTR) EV/Sales
As of 6 November 2026, Nektar Therapeutics (NKTR) trades at a EV/Sales of 19.2×. Over the past ten years it has ranged from 1.3× (March 2023) to 55.2× (March 2018); the current reading is higher than 69% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 17.6× | 294.24% |
| FY2024 | 4.5× | 28.74% |
| FY2023 | 3.5× | (21.83%) |
| FY2022 | 4.4× | (79.92%) |
| FY2021 | 22.0× | 36.01% |
| FY2020 | 16.2× | (37.15%) |
| FY2019 | 25.8× | 566.86% |
| FY2018 | 3.9× | (86.88%) |
| FY2017 | 29.5× | 178.35% |
| FY2016 | 10.6× | 6.62% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 38.9× | 26.42% |
| Mar 2026 | 30.8× | 75.39% |
| Dec 2025 | 17.6× | (16.10%) |
| Sep 2025 | 20.9× | 127.14% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DRTS Alpha Tau Medical Ltd. compare | n/m |
| GHRS GH Research PLC compare | n/m |
| LBRX LB Pharmaceuticals Inc compare | n/m |
| AVLN Avalyn Pharma Inc. compare | n/m |
| MNKD MannKind Corporation compare | 3.8× |
| URGN Urogen Pharma compare | 5.4× |
| OMER Omeros Corporation compare | 12.3× |
| NKTR Nektar Therapeutics | 19.2× |
| SLN Silence Therapeutics PLC Sponsored ADR compare | 1,025× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)